BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 27, 2019
View Archived Issues
Novel transgenic mouse model of memory impairment
Read More
Primary results show improvements in clinical outcomes in TOURMALINE-AL1 phase III study
Read More
'Love hormone' plays role in bones, fat
Read More
DNA circles drive neuroblastomas
Read More
Phase III study begins for first-line treatment of NSCLC with TAK-788
Read More
First functional oocytes derived from granulosa cells
Read More
Amgen identifies new KRAS G12C inhibitors
Read More
New eIF-2-alpha kinase GCN2 inhibitors discovered at RAPT Therapeutics
Read More
Idorsia Pharmaceuticals patents lysophosphatidic acid receptor 1 antagonists
Read More
Corcept Therapeutics presents glucocorticoid receptor antagonists
Read More
RAN protein is ALS target
Read More
RBM17 splicing factor maintains leukemia stem cell function in acute myeloid leukemia
Read More
Patient enrollment ongoing in phase I study of PF-06940434
Read More
Juventas Cell Therapy presents phase I data for CNCT-19 in acute lymphoblastic leukemia
Read More
RALA as a novel therapeutic target in triple-negative breast cancer
Read More
Pfizer initiates phase I study of PF-07062119
Read More
Agios Pharmaceuticals starts recruitment in phase III study of AG-881
Read More
Dosing of inarigivir stopped in phase II CATALYST program
Read More
Promising overall response and duration of response in phase IIa trial of PTX-200 in breast cancer
Read More
Roche and Genentech patent describes YAP1/TEAD interaction inhibitors
Read More
Baergic Bio enters agreements with AstraZeneca and Cincinnati Children's Hospital for AZD-7325
Read More
Clinical hold on PR-001 study in neuronopathic Gaucher's disease removed
Read More
